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breast cancer
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Background: A 21-gene recurrence score (RS) assay may inform adjuvant systematic treatment decisions in women
with early stage breast cancer. We sought to investigate the cost effectiveness of using the RS-assay versus current
clinical practice (CCP) in women with early-stage estrogen- or progesterone-receptor-positive, axilliary lymph-node
negative breast cancer (ER+/ PR + LN- ESBC) from the perspective of the Canadian public healthcare system.
Methods: We developed a Markov model to project the lifetime clinical and economic consequences of ESBC. We
evaluated adjuvant therapy separately in post- and pre-menopausal women with ER+/ PR + LN- ESBC. We assumed
that the RS-assay would reclassify pre- and post-menopausal women among risk levels (low, intermediate and high)
and guide adjuvant systematic treatment decisions. The model was parameterized using 7 year follow up data from
the Manitoba Cancer Registry, cost data from Manitoba administrative databases, and secondary sources. Costs are
presented in 2010 CAD. Future costs and benefits were discounted at 5%.
Results: The RS-assay compared to CCP generated cost-savings in pre-menopausal women and had an ICER of
$60,000 per QALY gained in post-menopausal women. The cost effectiveness was most sensitive to the proportion
of women classified as intermediate risk by the RS-assay who receive adjuvant chemotherapy and the risk of
relapse in the RS-assay model.
Conclusions: The RS-assay is likely to be cost effective in the Canadian healthcare system and should be
considered for adoption in women with ER+/ PR + LN- ESBC. However, ongoing assessment and validation of the
assay in real-world clinical practice is warranted.
Keywords: Breast cancer, Chemotherapy, Cost-effectiveness, 21-gene recurrence score assayBackground
In 2011, an estimated 23,200 women in Canada will be
diagnosed with breast cancer [1]. Approximately half of
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reproduction in any medium, provided the orbreast cancer (ER+/ PR+LN- ESBC) [2]. Standard care
for these patients usually includes local therapy (surgery
with or without radiation) followed by adjuvant system-
atic therapy such as endocrine therapy alone (tamoxifen
or aromatase inhibitors) or chemotherapy followed by
endocrine therapy [3]. Canadian guidelines specify that a
patient’s risk of recurrence can be classified as low, inter-
mediate or high and that adjuvant chemotherapy may be
added when the benefits of treatment outweigh toxicities
of therapy [4]. However, evaluating the risks and benefits
of chemotherapy based on the Canadian guidelines isal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inform the guidelines are not accurate predictors of risk
or benefits of chemotherapy [4-8]. A validated software
program Adjuvant!Online (AOL) has been developed
that projects outcomes at 10 years to assist oncologists in
adjuvant decision-making process. However, AOL is also
based on histopathologic measures.
The 21-gene recurrence score assay (Oncotype DX)
produces a “tumour signature” reflecting tumour biology
and risk of relapse [7,9]. An algorithm produces a con-
tinuous variable known as the “recurrence score” (RS)
reflecting prognosis, which ranges from 1 (lower risk) to
100 (higher risk), based on the expressions of the 21
genes isolated from tumour samples. Women with a
score of less than 18 have a low risk of recurrence and
typically have good outcomes from endocrine therapy
alone , whereas those with a score of 31 or more have a
high risk of recurrence and gain the largest expected
benefit from the addition of chemotherapy to endocrine
therapy. Women with a score between 18 and 30 have
an intermediate risk and do not appear to have a large
benefit from chemotherapy but the uncertainty in the
estimate cannot exclude a clinically important benefit
[9,10].
The prognostic and predictive value of the RS-assay in
women with ER+/PR+LN- ESBC was evaluated in
retrospective analyses of the National Surgical Adjuvant
Breast and Bowel Project (NSABP) chemotherapy-
tamoxifen trials (B-14 and B-20) [7,9,11] in the United
States. It was shown that among ER+/PR+LN- ESBC
patients, approximately, 51% had a low RS, 22% a inter-
mediate RS, and 27% a high RS [7,9,11]. The assay was
found to be more accurate than histologic measures
alone in predicting the likelihood of breast cancer recur-
rence (both loco-regional [11] and distant recurrence
[7,9]) and patient survival within 10 years of initial diag-
nosis [9], as well as benefit from adjuvant chemotherapy
[9,11]. Additionally, clinical significance of the RS-assay
has been reported in the Asian population [12].
In 2007 the RS-assay was recommended in the Na-
tional Comprehensive Cancer Network and American
Society for Clinical Oncology guidelines as “evidence-
based” to guide the use of adjuvant chemotherapy in all
women with ER+/ PR+LN- ESBC [13,14]. Public cover-
age of the 21-gene assay is limited and inconsistent
across Canada. However, the use of the test with reim-
bursement mechanisms is likely increasing. It is available
in Ontario through “out-of-country health services”
which requires a request from an oncologist and pre-
approval [15,16]. In 2010 the Ontario Health Technology
Advisory Committee (OHTAC) recommended that the
assay be made available “within the context of a field
evaluation” [17]. It is also available in a limited fashion
in British Columbia and Quebec [16]. The test is notwidely used and in 2010 less than 1000 patients received
the test across Canada [16] but few field evaluations to
establish its impact on Canadian practice are ongoing in
British Colombia and Ontario.
According to the Annual Report Card of the Cancer
Advocacy Coalition of Canada, the RS-assay will cost
$4,000 CAD per patient including all Canadian system
expenses [15]. Previous cost-effectiveness analyses of the
RS-assay in women with ER+/ PR+LN- ESBC in the US
[18,19], Japan [20,21], Israel [22] and Canada [23,24]
suggested that it is likely to be cost saving or cost effective
in this patient group. However, findings from studies in
Israel [22] and Japan [19,20] cannot be extrapolated to
the Canadian context because of possible variations in
clinical practice and different approaches to pricing and
reimbursement. Additionally, analyses from the US [18,19]
and Canada [23,24] did not use all relevant data and suffer
from other limitations as indicated elsewhere [25].
Generation of recommendations for Canadian clinical
practice guidelines regarding the use of RS-assay
requires a comprehensive health economic evaluation of
the assay in the Canadian setting. The purpose of this
study was to conduct a cost-effectiveness analysis of the
RS-assay versus current clinical practice (CCP) regarding
adjuvant chemotherapy treatment in women with ER+/




We developed a decision analytic model (Figure 1) to
project the lifetime clinical and economic consequences
of ER+/ PR+LN- ESBC under two different treatment
strategies. The model begins with a decision to use the
RS-assay or to continue with CCP (Figure 1a). We
assumed that each strategy (RS or CCP) classifies
patients into three risk levels (low, intermediate and
high) and corresponding treatment regimens (endocrine
therapy plus chemotherapy or endocrine therapy alone).
Patients receiving endocrine therapy alone entered
model “E” (Figure 1b) and those receiving chemotherapy
plus endocrine therapy entered model “C” (Figure 1c).
Model “E” simulated monthly transitions among the
following four distinct health states: (1) remission; (2)
loco-regional recurrence (LR); (3) distant recurrence
(DR); (4) death. Model “C” simulated monthly transi-
tions among the following five distinct health states: (1)
remission with no chemotherapy-related serious adverse
effects (CSAE); (2) remission with CSAE; (3) LR; (4) DR;
(5) death.
We used a lifetime horizon and half cycle correction
[26]. Future costs and benefits were discounted at 5%
annually following Canadian guidelines [27]. Data collec-
tion and analysis involving Manitoba administrative
a RS-assay versus Canadian clinical practice±. 
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c  Schematic representation of the Markov model structure “C”†‡.
± The risk classification criteria in the Canadian clinical practice arm was based on the Canadian clinical practice 
guidelines for adjuvant systemic therapy for women with node-negative breast cancer 4.  
* Patients entering Markov model “E” start the model and remain in the remission state unless they relapse (LR, DR or 
Dead).  
† Patients entering Markov model “C” start the model in the remission state with no CSAE. Within the first cycle patients 
may develop CSAE. These patients will make a transition to the remission state with CSAE. During the first cycle, 
patients also may transition to DR, LR and Dead states. After the first cycle, patients may remain in the two remission 
states unless they relapse in to LR, DR or Dead.  
‡ In both Markov models, patients who developed LR, remain in the LR state or make transition to DR or Dead states. 
Patients who developed DR remain in the DR state or make transition to the Dead state. The cycle length was 1 month. 








Figure 1 (See legend on next page.)
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Figure 1 Decision model for early stage breast cancer. a RS-assay versus Canadian clinical practice±. b Schematic representation of the
Markov model structure “E”*{. c Schematic representation of the Markov model structure “C”†{.± The risk classification criteria in the Canadian
clinical practice arm was based on the Canadian clinical practice guidelines for adjuvant systemic therapy for women with node-negative breast
cancer [4] * Patients entering Markov model “E” start the model and remain in the remission state unless they relapse (LR, DR or Dead).
† Patients entering Markov model “C” start the model in the remission state with no CSAE. Within the first cycle patients may develop CSAE.
These patients will make a transition to the remission state with CSAE. During the first cycle, patients also may transition to DR, LR and Dead
states. After the first cycle, patients may remain in the two remission states unless they relapse in to LR DR or Dead. { In both Markov models,
patients who developed LR, remain in the LR state or make transition to DR or Dead states. Patients who developed DR remain in the DR
state or make transition to the Dead state. The cycle length was 1 month. LR, loco-regional recurrence; DR, distant recurrence; CSAE,
chemotherapy-related serious adverse effects.
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Hospital Discharge Database, the Physician Claims Data-
base and the Drug Program Information Network) were
approved by the University of Manitoba Health Re-
search Ethics Board.
Risk distribution and transition probabilities
The Manitoba Cancer Registry is a provincial database
that contains records for more than 99.5% of all cancer
patients in Manitoba [28]. Information on breast cancer
staging, based on the American Joint Commission on
Cancer (version 5), has been collected for breast cancers
diagnosed since January 1995 [29]. We used the Registry
to identify a study cohort consisting of all pre-
menopausal (defined as age <50 years) and post-
menopausal (age ≥50 years) women living in Manitoba
diagnosed with ER+/ PR+LN- ESBC (stage I/II) during
the period from January 1, 2000 to December 31, 2002.
Although data on human epidermal growth factor recep-
tor 2 (HER2) status were not collected by the registry
during this time frame, the majority of these women are
likely HER2 negative since women with HER2 positive
are only found in approximately 10% to 15% of endo-
crine positive breast cancers such as those in our study
population [30-34]. We used data from women diag-
nosed during this period so that a long follow up period
would be available. Seven-year follow-up information
from the time of diagnosis was available for each patient.
This included breast cancer recurrence (LR and DR) and
treatments (surgery, radiation therapy, endocrine therapy
and chemotherapy). We linked the study cohort identi-
fied using the Registry with administrative data held by










2000− 2002 109 389
2003− 2005 106 506
† Chi-square test.Hospital Discharge Database, the Physician Claims Data-
base and the Drug Program Information Network. To
protect confidentiality, the linkage in this study was per-
formed, via scrambled health number, using anonymized
versions of these databases.
To verify that the proportion of women who received
adjuvant chemotherapy in our study cohort would re-
flect more recent clinical practice regarding adjuvant
chemotherapy administration, we examined a second
cohort, consisting of all women diagnosed between
January 1, 2003 and December 31, 2005 (Table 1). We
did not find the proportion receiving adjuvant chemo-
therapy to differ between the two time periods (chi-
square test, level of significance of 0.05) and thus used
the earlier time period with longer follow-up data to
parameterize the model.
For the CCP model we estimated the risk distribution
and proportion receiving chemotherapy within each risk
level (Table 2). According to the Canadian clinical practice
guidelines, risk can be specified on the basis of tumour
size, histologic or nuclear grade, and lymphatic and vascu-
lar invasion [4]. The Manitoba Cancer Registry collects
this information with the exception of lymphatic and vas-
cular invasion. Given the significant correlation between
tumour size and lymphatic and vascular invasion [35], we
classified pre- and post-menopausal women for this ana-
lysis as belonging to three risk levels (low, intermediate
and high risk) on the basis of tumour size and histologic
or nuclear grade only. We defined current clinical practice
according to the observed administration of adjuvant ther-
apy in the ER+/ PR+LN- ESBC cohort during the study
period. We conducted survival analyses using Kaplan-
Meier estimates for pre- and post-menopausal womenchemotherapy by diagnosis time period and menopausal
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Risk classification by CCP (%)
High risk 21.1 15.8 – 32.6 22.3 18 – 27 Dirichlet MCR
Chemotherapy-treated women 100 85.1 – 100 53.8 43 – 64.4 Beta MCR and PC
Intermediate risk 72.6 62.9 – 80.6 52.3 47 – 57.5 Dirichlet MCR
Chemotherapy-treated women 65.2 53.4 – 75.4 14.2 9.9 – 20 Beta MCR and PC
Low risk 6.3 0 – 10 25.4 21.2 – 30.2 Dirichlet MCR
Chemotherapy-treated women 16.7 10 – 20 3.4 0 – 10 Beta MCR and PC
Overall chemotherapy-treated women
by CCP (%)
69 60 – 83 19 13 – 27.7 MCR and PC
Risk classification by RS-assay (%)
High risk 27.7 22.9– 33.1 23.1 18.7 – 28.3 Dirichlet [9]
Chemotherapy-treated women 100 90 – 100 100 90 – 100 Beta [9]
Intermediate risk 19.5 15.4 – 24.4 21.5 17.1 – 26.5 Dirichlet [9]
Chemotherapy-treated women 50 0 – 100 50 0 – 100 Beta [22,39,40,65]
Low risk 52.6 46.9 – 58.3 55.4 49.7 – 61 Dirichlet [9]
Chemotherapy-treated women 0 0 – 10 0 0 – 10 Beta [9]
Overall chemotherapy-treated women
by RS-assay (%)
37.5 30 – 47.8 33.8 27 – 44.3 [9,22,39,40,65]
Chemotherapy-related serious
adverse effects (%)
2.5 0 – 10.6 4 0 – 12.3 Beta MCR and HA
Health-State Utilities{
Remission state
Remission on chemotherapy regimen
with
Minor or no toxicity 0.85 −20% 0.783 −20% 6 months Beta [51,52,55]
Remission on chemotherapy regimen
with
Major toxicity 0.623 −20% 0.577 −20% 6 months Beta [51,52,55]
Remission after chemotherapy regimen 0.872 −20% 0.808 −20% Life Beta [51,54]
Remission on hormonal therapy 0.881 −10% – +10% 0.816 −10% – +10% 60 months Beta [51,52,55]
Remission after hormonal therapy 0.89 −10% – +10% 0.824 −10% – +10% Life Beta [51,52,55]
Loco-regional recurrence, under
treatment
0.623 −10% – +10% 0.577 −10% – +10% 12 month Beta [41,51,52,55]
Loco-regional recurrence, after
treatment
0.757 −10% – +10% 0.700 −10% – +10% Life time Beta [41,51,52,55]
Distant recurrence 0.445 −10% – +10% 0.412 −10% – +10% Life time Beta [41,51,52,55]
Death state 0 0
Cost associated with remission
(per month), $
First year after diagnosis with ESBC
Cost of surgerya 3390 3000 – 3780 3642 3384 – 3900 One time LogNormal PC, HA and
CL
Cost of radiation therapyb 3410 2737 – 4252 3027 2430 – 3776 One time LogNormal PC and CL
Cost of endocrine therapyc
Tamoxifen 12.4 11.6 – 13.2 12.4 11.6 – 13.2 12 months LogNormal DPIN
Aromatase inhibitors 156 120 – 193 12 months LogNormal DPIN
Aromatase + tamoxifen 72 62 – 81 12 months LogNormal DPIN
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CMF 478 823 5 months LogNormal MCR
AC 806 1918 3 months LogNormal MCR
FAC 924 1270 5 months LogNormal MCR
TAC 2455 2800 5 months LogNormal MCR
Weighted average cost of
chemotherapy regimense
5 months LogNormal MCR
First three months on chemotherapy 1142 1099 3 months LogNormal MCR
Next 419 432 2 months LogNormal MCR
Cost of CSAEf 1263 978 – 1581 1,750 1376-2168 During
chemotherapy
LogNormal PC, HA and
CL
Surveillanceg
Low risk 79 47 – 111 74 62 – 85 12 months LogNormal PC
Intermediate risk 93 76 – 108 66 60 – 68 12 months LogNormal PC
High risk 106 78 – 133 77 69 – 82 12 months LogNormal PC
After first year of diagnosis with ESBC
Cost of endocrine therapyc
Tamoxifen 12.4 11.6 – 13.2 12.4 11.6 – 13.2 48 months LogNormal DPIN
Aromatase inhibitors 156 120 – 193 48 months LogNormal DPIN
Aromatase + tamoxifen 72 62 – 81 48 months LogNormal DPIN
Surveillanceg
Low risk 39 18 – 59 33 30 – 54 Life time LogNormal PC
Intermediate risk 35 32– 40 45 38 – 53 Life time LogNormal PC
High risk 102 65 – 126 39 32 – 45 Life time LogNormal PC
Cost associated with LR (per month), $
First year after LR
Cost of surgerya 3522 889 – 7280 2806 1068 – 3111 One time LogNormal PC, HA and
CL
Cost of radiation therapyb 1098 878 – 1371 2120 1695 – 2651 One time LogNormal PC, HA and
CL
Cost of endocrine therapyc
Tamoxifen 12.4 11.6 – 13.2 12.4 11.6 – 13.2 12 months LogNormal DPIN
Aromatase inhibitors 156 120 – 193 12 months LogNormal DPIN
Sequential aromatase! tamoxifen 72 62 – 81 12 months LogNormal DPIN
Cost chemotherapyd 278 181 – 619 311 200 – 688 5 months LogNormal PC and CL
Surveillance during first yearg 118 48 – 189 123 64 – 179 12 months LogNormal PC
After first year of LR
Cost of endocrine therapyc
Tamoxifen 12.4 11.6 – 13.2 12.4 11.6 – 13.2 48 months LogNormal DPIN
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Aromatase inhibitors 156 120 – 193 48 months LogNormal DPIN
Sequential aromatase! tamoxifen 72 62 – 81 48 months LogNormal DPIN
Surveillance after first year of LRg 98 33 – 162 78 18 – 139 Life time LogNormal PC
Cost associated with DR (per month), $
First year after DR
Hospitalization cost 841 138 – 253 1569 185– 3177 12 months LogNormal HA and CL
Physicians cost 247 64 – 431 353 205 – 501 12 months LogNormal PC
Drugs cost 19 5 – 34 83 29 – 134 12 months LogNormal DPIN
After first year of DR
Hospitalization cost 1293 146 – 3014 783 72 – 1618 Life time LogNormal HA and CL
Physicians cost 204 86 – 322 183 62 – 337 Life time LogNormal PC
Drugs cost 52 5 – 121 100 33 – 167 Life time LogNormal DPIN
† Beta distribution was used for other probability parameter estimates not included in this table.
{ The baseline utility for post-menopausal women aged 50 to 80 was 0.824 and for premenopausal women aged 20 to 49 was 0.89 [51]. We derived utilities for
each state by multiplying these baseline utility values by utility estimates for women with breast cancer [41,52-54], consistent with methodology as described by
Fryback [55].
a Cost of breast cancer surgery: We used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost of hospitalization due to
any breast cancer surgery (including one day hospitalization and using the ICD-9-CM procedure codes for a hospital abstract) within one year after diagnosis with
ESBC and LR by menopausal status.
b Cost of radiation therapy: Cost of radiation therapy included cost of radiation therapy–related physician claims in addition to administrative cost. We used the
Physician Claims Database to estimate the mean cost of radiation therapy–related physician claims (using the tarrif code for a medical claim) within one year after
diagnosis with ESBC and LR by menopausal status. Administrative costs were derived from the cost list for Manitoba health services.
c Cost of endocrine therapy: We used the Drug Program Information Network to estimate the mean cost of tamoxifen and aromatase inhibitors by menopausal
status (using the drug identification number for a drug claim) within the time periods, between diagnosis with ESBC and before any relapse, and diagnosis with
LR and before any relapse.
d Cost of chemotherapy: Nursing, overhead and administration costs were derived from the cost list for Manitoba health Services. We used the Physician Claims
Database to estimate the mean cost of chemotherapy–related physician claims costs (using the tarrif code for a medical claim) within one year after diagnosis
with ESBC and LR by menopausal status. Chemotherapy regimens costs were estimated based on the market prices as of May 2010.
e Weighted average cost of adjuvant chemotherapy regimens: We calculated the average cost of adjuvant chemotherapy regimens weighted to the observed
proportion use of anthracyclines and taxanes by menopausal status. Weighted average cost of adjuvant chemotherapy regimens = proportion of women received
non-anthracyclines containing adjuvant chemotherapy × cost of CMF+proportion of women received anthracyclines containing adjuvant chemotherapy (no
added taxanes) × cost of AC+proportion of women received anthracyclines and taxanes containing adjuvant chemotherapy × cost of TAC.
f Cost of CSAE: We used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost associated with hospitalizations due to
any of the eight diagnoses which were considered CSAE among women who develop CSAE. We stratified the analysis by menopausal status.
g Cost of surveillance: We defined the cost of breast cancer surveillance as the incremental cost of health care utilization (medical claims) after diagnosis with
ESBC versus the time before diagnosis. We used the Physician Claims Database to collect medical claims for both post- and pre-menopausal women, within
3 years before and 7 years after diagnosis with ESBC. We estimated the mean cost of medical claims by menopausal status within 3 years before diagnosis in
order to reflect the usual cost of health care utilization. We calculated the incremental mean cost of health care utilization by menopausal status during the
period from diagnosis with ESBC and before any relapse (excluding cost of claims related to surgery, radiation therapy, chemotherapy and CSAE) stratified by the
time following diagnoses (first year versus later). Similarly, we calculated the incremental mean cost of health care utilization by menopausal status after LR
PSA =probabilistic sensitivity analysis; MCR=Manitoba Cancer Registry: PC = physician claims; HA=hospital abstracts; CL = cost list for Manitoba health services;
DPIN =Drug Program Information Network records; ESBC= early stage breast cancer; LR, loco-regional recurrence; DR= distant recurrence; CMF= 6 cycles of
cyclophosphamide, methotrexate, 5-fluorouracil; AC = 4 cycles of adriamycin, cyclophosphamide; FAC = 6 cycles of fluorouracil, doxorubicin, cyclophosphamide;
TAC = 6 cycles of docetaxel, doxorubicin, cyclophosphamide; CCP = current clinical practice.
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using 7 years of follow up data from the Manitoba Cancer
Registry, and used this information to estimate all transi-
tion probabilities in the CCP Markov models.
For the RS-assay model, we derived the risk distribution
and monthly transition probabilities from remission to
LR, DR and Death over 10 years within each risk level
from retrospective analyses of the NSABP chemotherapy-
tamoxifen trials (B-14 and B-20) (Table 2) [9,11]. Investi-
gators from the B-14 and B-20 studies provided Kaplan
Meier curves for LR, DR and death events stratified byrisk level. To account for menopausal status, we adjusted
all transition probabilities derived from these summary
statistics based on corresponding risk ratios (for LR, DR
and death) comparing pre- to post-menopausal women
derived from our studied ESBC cohort. The risk ratios
were weighted using the menopausal status balance
reported in the B-14 and B-20 trials [9,11].
There is still uncertainty as to whether chemotherapy
is necessary for women with intermediate risk. Reported
usage in this group varies, including estimates of 56%
[36], 50% [37], 47% [38], 38% [39], 33% [22], and 26%
Table 3 Characteristics of 489 patients diagnosed during the time period of 2000 to 2002 with ER+or PR+1–3
LN+ESBC stratified by menopausal status and risk of recurrence using Canadian clinical practice guidelines














(n = 11) (n = 78) (n = 20) (n = 109) (n = 115) (n = 196) (n = 78) (n = 389)
Age ( years)
Mean (range) 41.8 43.6 42.7 43 63.4 64 61.8 63
(30 – 49) (29 – 49) (33–49) (29–49) (50–85) (50 – 88) (50–86) (50–88)
<40 3 (27.3) 17 (21.8) 4 (20) 24 (22) - - - -
40 – 49 8 (72.7) 61 (78.2) 16 (80) 85 (78) - - - -
50 – 64 - - - - 64 (55.7) 111 (56.6) 53 (68) 228 (58.6)
≥65 - - - - 51 (44.3) 85 (43.4) 25 (32) 161 (41.4)
Primary tumour size – no.
of women (%)
<2 cm 11 (100) 51 (65.4) 7 (35) 69 (63.3) 115 (100) 117 (59.7) 17 (21.8) 260 (66.8) .78
2-5 cm 0 27 (34.6) 11 (55) 38 (34.9) 0 79 (40.3) 55 (70.5) 123 (31.7)
>5 cm 0 0 2 (10) 2 (1.8) 0 0 6 (7.7) 6 (1.5)
Receptor status – no.
of women (%)
ER + and PR- 0 11 (14.1) 7 (35) 18 (16.6) 25 (21.7) 54 (27.5) 30 (38.5) 109 (28) .016
ER- and PR+ 0 4 (5.2) 3 (15) 7 (6.4) 1 (0.9) 4 (2.1) 6 (7.7) 11 (2.8)
ER + and PR+ 11 (100) 63 (80.7) 10 (50) 84 (77) 89 (77.4) 138 (70.4) 42 (53.8) 269 (69.2)
Tumour grade – no.
of women (%)
1 6 (54.5) 14 (18) 1 (5) 21 (19.3) 89 (77.4) 17 (8.7) 1(1.3) 107 (27.5) .37
2 0 50 (64.1) 5 (25) 55 (50.5) 0 160 (81.6) 21 (26.9) 181 (46.5)
3 0 5 (6.4) 14 (70) 19 (17.4) 0 6 (3) 53 (68) 59 (15.2)
Unknown 5 (45.5) 9 (11.5) 0 14 (12.8) 26 (22.6) 13 (6.7) 3 (3.8) 42 (10.8)
Stage
I 11 (100) 55 (70.5) 7 (35) 73 (67) 115 (100) 145 (74) 21 (26.9) 281 (72.2) .56
IIA 0 23 (29.5) 11 (55) 34 (31.2) 0 51 (26) 51 (65.4) 102 (26.2)
IIB 0 0 2 (10) 2 (1.8) 0 0 6 (7.7) 6 (1.6)
With Breast-surgery{− no.
of women (%)
11 (100) 78 (100) 20 (100) 109 (100) 115 (100) 196 (100) 78 (100) 389 (100)
Breast-conserving surgery 8 (72.7) 51 (65.4) 9 (45) 68 (62.4) 65 (56.5) 113 (57.7) 29 (37.2) 207 (53.4) .08
Mastectomy 3 (27.3) 27 (34.6) 11 (55) 41 (37.6) 50 (43.5) 83 (42.3) 49 (62.8) 182 (46.6)
With Radiotherapy{− no.
of women (%)
7 (63.6) 51 (65.4) 11 (55) 69 (63.3) 62 (54) 109 (55.6) 30 (38.5) 201 (51.7) .03
With Endocrine therapy{− no.
of women (%)
5 (45.4) 65 (83.3) 18 (90) 88 (81) 91 (79.1) 165 (84.1) 53 (67.9) 309 (79.4) .76
Tamoxifen 5 (100) 49 (75.4) 13 (72) 67 (76.1) 61 (67) 104 (63) 31 (58.5) 196 (63.4) .02
Aromatase inhibitors + tamoxifen 0 13 (20) 4 (22) 17 (19.3) 25 (27.5) 48 (29) 18 (34) 91 (29.5)
Aromatase inhibitors 0 1 (1.5) 0 1 (1.2) 5 (5.5) 10 (6) 3 (5.7) 18 (5.8)
Unknown type 0 2 (3) 1 (5.5) 3 (3.4) 0 3 (2) 1 (1.8) 4 (1.3)
With adjuvant chemotherapy{− no.
of women (%)
3 (27.3) 51 (65.4) 20 (100) 74 (69) 3 (2.6) 28 (14.3) 42 (53.8) 73 (18.8) <.0001
No anthracyclines 0 17 (33.3) 5 (25) 22 (35.6) 1 9 (32.1) 16 (38.1) 26 (29.7) .88
Anthracyclines, no taxanes 3 (100) 29 (56.9) 12 (60) 44 (54.8) 1 16 (57.1) 23 (54.8) 40 (59.5)
Anthracyclines and taxanes 0 2 (3.9) 2 (10) 4 (4.1) 0 0 3 (7.1) 3 (5.4)
Unkown type 0 3 (5.9) 1 (5) 4 (5.5) 1 3 (10.8) 0 4 (5.4)
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Table 3 Characteristics of 489 patients diagnosed during the time period of 2000 to 2002 with ER+or PR+1–3
LN+ESBC stratified by menopausal status and risk of recurrence using Canadian clinical practice guidelines (Continued)














(n = 11) (n = 78) (n = 20) (n = 109) (n = 115) (n = 196) (n = 78) (n = 389)
Loco-regional recurrence event – no.
of women (%)
0 4 (5.1) 2 (10) 7 (6.4) 1 (.86) 2 (1) 10 (12.8) 13 (3.3) .14
Distant recurrence event – no.
of women (%)
0 3 (3.8) 3 (15) 6 (5.5) 2 (1.7) 10 (5.1) 14 (17.9) 26 (6.7) .65
Deaths – no. of women (%) 0 3 (3.8) 3 (15) 6 (5.5) 10 (8.6) 31 (15.8) 22 (28.2) 63 (16.2) .004
Charlson co-morbidity score
mean (SE, range)
0 0.10 0.05 0.08 0.11 0.20 0.19 0.18 .028
(0.03, 0–2) (0.03, 0–6)
Charlson co-morbidity score – no.
of women (%)
0 11 (100) 71 (91) 19 (95) 101(92.6) 104 (90.4) 171 (87.3) 69 (88.4) 344 (88.4) .86
1 0 6 (7.7) 1 (5) 7 (6.4) 9 (7.8) 18 (9.2) 6 (7.7) 33 (8.4)
2 0 1 (1.3) 0 1 (1) 2 (1.8) 3 (1.5) 1 (1.3) 6 (1.5)
3 0 0 0 0 0 2 (1) 1 (1.3) 3 (.8)
4 0 0 0 0 0 0 1 (1.3) 1 (.3)
5 0 0 0 0 0 1 (.5) 0 1 (.3)
6 0 0 0 0 0 1 (.5) 0 1 (.3)
* Categorization of a patient’s risk for recurrence as low, intermediate, or high was according to the Canadian clinical practice guidelines [4]. Low risk: Post-
menopausal women with primary tumour size < 2 cm and tumour grade= 1; pre-menopausal women with primary tumour size < 1cm and tumour grade =1. High
risk: All women with tumour size >3 cm, or women with tumour size≥ 1 cm and≤ 3 cm with tumour grade = 3. Intermediate risk: Post-menopausal women with
tumour size < 2 cm and tumour grade> 1, or tumour size≥ 2 cm and< 3 cm and tumour grade = 1 or 2; premenopausal women with tumour size < 1 cm and
tumour grade >, or tumour size≥ 1 cm and< 3 cm and tumour grade= 1 or 2. Given the significant correlation between tumour size, lymphatic and vascular
invasion [35], and tumour grade [66], lymphatic and vascular invasion was not used in categorizing patients’ risk because the Manitoba cancer registry does not
collect this information and 52 patients ‘risk for recurrence was categorized on the basis of tumour size only because their tumors size < 3 cm with undetermined
tumours grade.
† The p-value was calculated for overall pre- vs. overall post-menopausal women. Fisher’s exact and chi-square tests were used for binary and categorical variables
respectively. Distributions of continuous variables were summarized by their means and standard errors and compared using t-tests.
{ Women were defined as having received any of these treatments for their primary breast cancer if the International Classification of Disease, Ninth Revision,
Clinical Modification (ICD-9-CM) procedure code or the Canadian Classification of Health Interventions (CCI) procedure code of any of these treatments was found
before any recurrence, second primary cancer or death within one year of diagnosis with ESBC.
Co-morbid diagnoses were considered present if they were found during one year before and 6 months after the diagnosis with primary breast cancer.
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the intermediate risk group would receive adjuvant
chemotherapy.
There is no data suggesting that outcomes after first
relapse are affected by the primary adjuvant therapy
received [41]. Thus, we assumed that transition prob-
abilities following first relapse in the RS-assay model
would be the same as those in the CCP model.
To extrapolate beyond the follow-up period of the
ESBC cohort and the clinical trials used for this study,
we assumed that the observed average monthly transi-
tion probabilities from remission to LR, DR and Death
during the last observed year of follow-up would be con-
stant over the extrapolated lifetime. We used female
age-adjusted life tables for Manitoba to adjust the prob-
abilities from remission to death in order to account for
the incremental mortality risk over the extrapolated time
[42].Adjuvant chemotherapy regimens
In Canada, from 2000–2002, two adjuvant chemotherapy
regimens were recommended for women with ER+/
PR+LN- ESBC: (1) 6 cycles of cyclophosphamide,
methotrexate, 5-fluorouracil (CMF) or (2) anthracycline-
containing chemotherapy regimen such as 4 cycles of
doxorubicin (adriamycin), cyclophosphamide (AC) or
6 cycles of fluorouracil, doxorubicin, cyclophosphamide
(FAC) [4]. Four cycles of AC has been used preferentially
as a component of chemotherapy regimens for the adju-
vant treatment of ESBC [43]. Recently, chemotherapy
regimens containing taxanes, such as 6 cycles of doce-
taxel, doxorubicin, cyclophosphamide (TAC), have been
recommended for the LN- ESBC population [44].
The majority of adjuvant chemotherapy-treated women
in our study cohort received anthracycline-containing adju-
vant chemotherapy regimens (Table 3). Information on spe-
cific chemotherapy agents (e.g. CMF, AC, FAC, and TAC)
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anthracycline-containing adjuvant chemotherapy regimens
received 6 cycles of CMF; that patients who received
anthracycline-containing adjuvant chemotherapy regimens
with no added taxanes received four cycles of AC; and that
patients who received anthracycline and taxane-containing
adjuvant chemotherapy regimens received 6 cycles of TAC.
Thus, in the base case analysis, we used the weighted aver-
age cost of CMF, AC and TAC.
Anthracycline-containing regimens may have a sur-
vival advantage compared to CMF regimens [45]. How-
ever, other studies showed anthracycline-containing
regimens to have equivalent clinical outcomes compared
to CMF regimens, particularly in women with favourable
prognostic features (LN-, ER+/PR+) such as our study
cohort [4,46,47]. Thus, in sensitivity analysis we consid-
ered each of the CMF, AC, FAC and TAC regimens sep-
arately as the standard adjuvant chemotherapy regimen
for women with ER+/ PR+LN- ESBC.
Adjuvant chemotherapy-related serious adverse effects
(CSAE)
We defined CSAE as hospitalization for any of the fol-
lowing eight diagnoses (as defined by their ICD-9-CM
diagnosis and procedure codes) occurring within one
year of diagnosis with ESBC: 1) abnormal electrolytes or
dehydration; 2) constitutional symptoms and nonspecific
symptoms associated with therapy; 3) nausea, emesis,
and diarrhea; 4) infection and fever; 5) malnutrition;
6) anemia and red cell transfusion; 7) neutropenia or
thrombocytopenia; 8) deep venous thrombosis or pul-
monary embolus [48,49]. These diagnoses were selected
based on their association with chemotherapy in previ-
ous clinical trials [3]. We estimated the incremental rate
of occurrence of CSAEs from the frequency of occur-
rence of these ICD-9 codes in hospital abstracts of adju-
vant chemotherapy recipients versus non-recipients,
stratified by menopausal status and adjusting for comor-
bidity indices using the method developed by Charlson
et al. excluding cancer diagnoses [50].
Costs
Treatment costs, including surgery, radiation therapy,
chemotherapy, endocrine therapy, surveillance, and
CSAE, are all publicly funded in Manitoba and are thus
recorded in the administrative databases. For each pa-
tient in the studied cohort we gathered all treatment
costs for the first 7 years following diagnosis with pri-
mary breast cancer (Table 2). We used this to estimate
the cost per unit time in each Markov state.
Utilities
The baseline utility for post-menopausal women aged 50
to 80 was 0.824 and for premenopausal women aged 20to 49 was 0.89, based on representative values for the
U.S. population [51]. We derived utilities for each health
state by multiplying these baseline utility values by utility
estimates for women with early-stage breast cancer
[41,52-55] (Table 2). We performed sensitivity analysis
on the utility values after chemotherapy to account for
potential long term side effects of primary adjuvant
chemotherapy [56].
Results
Patient, tumour, treatment and event characteristics of
the study cohort are summarized in Table 3. There were
109 pre-menopausal and 389 post-menopausal women
diagnosed with ER+/ PR+LN- ESBC in Manitoba from
January 1, 2000 to December 31, 2002. The median age
was 44 years (range 29–49 years) in pre-menopausal
women and 62 years (range 50–88) in post-menopausal
women. All pre- and post-menopausal women received
surgery (mastectomy or breast-conserving surgery) for
their primary breast cancer. Adjuvant therapy including
radiation therapy, endocrine therapy (tamoxifen or aro-
matase inhibitors) and chemotherapy were administered
in 63%, 81% and 69% of pre-menopausal women, re-
spectively, and in 52%, 79% and 19% of post-menopausal
women, respectively.
In pre-menopausal women, the RS-assay led to an in-
crease of 0.05 QALY per person and decrease in cost of
$50 per person resulting in a cost saving compared to
CCP. In post-menopausal women, the RS-assay led to an
increase of 0.062 QALY per person and an increase in
cost of $3,700 per person, resulting in an incremental
cost effectiveness ratio (ICER) of approximately $60,000
per QALY gained compared to CCP.
Sensitivity analysis
In the base case we compared the RS assay versus CCP
when the weighted average cost of CMF, AC and TAC
was used. We considered each of CMF, AC, FAC and
TAC regimens separately as the standard adjuvant
chemotherapy regimen for women with ER+/ PR+LN-
ESBC in sensitivity analysis. In premenopausal women,
the RS-assay stayed cost saving with each of CMF, AC,
FAC and TAC regimens. In post-menopausal women,
the RS-assay had an ICER of $59,800 per QALY gained
with CMF, $58,200 per QALY gained with AC, $65,000
per QALY gained with FAC and $83,100 per QALY
gained with TAC. The utility during chemotherapy and
the rates and costs of CSAE did not substantially influ-
ence the results with any regimen.
We performed threshold analyses on the proportion of
chemotherapy-treated women classified as being in the
intermediate risk group by the RS-assay, on the risk of re-
lapse in the RS-assay model and other parameters found
to influence our base case analyses (Tables 4 and 5).
Table 4 Summary of important one-and two way sensitivity analysesa
Interpretation of the incremental impact of the RS-assay compared to CCP


















Chemotherapy treated women in intermediate
risk group by the RS-assay (0% to 100%)
0% to 42% 43% to 63% 64% to 100%
Change in absolute risk of relapseb in the
RS-assay model (−10% to +10%)
> +1.8% ≤ +1.8%
Change in utility of
recurrencec (−10% to +10%)
Lower limit cost
of recurrencec
≤ +2.2% +2.3% to +3.4% +3.5% to +4% ≥ +4%
Baseline cost of
recurrencec
> +3% ≤ +3%
Upper limit cost
of recurrencec
> +3% ≤ +3%
Change in utility following adjuvant
chemotherapy (−10% to +10%)
> +1% ≤ +1%
CMF= 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC = 4 cycles of adriamycin, cyclophosphamide; CCP = current clinical practice.
a Values in the table show how the incremental impact of the RS-assay compared to CCP changes, over 6 significant ranges, depending on the values of certain
key parameters. For example, if between 43-63% of women identified as intermediate risk by the RS-assay were to receive chemotherapy, then the RS-assay
would be cost saving relative to CCP; if this proportion is 64% or greater, then the RS-assay has an ICER between 0 and $20,000 / QALY gained.
b Relapse includes loco-regional recurrence, distant recurrence and death due to any cause.
c Recurrence includes loco-regional and distant recurrences.
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negative incremental cost and effect (the RS-assay led to
decrease in both cost and effect) and when fewer than
43% of women in the RS-assay intermediate risk group
received adjuvant chemotherapy. Among postmenopausal
women, the RS-assay was dominated by CCP when fewer
than 31% of women in the RS-assay intermediate riskTable 5 Summary of important one-and two way sensitivity a
Interpretation of the incremental impa









Chemotherapy treated women in intermediate
risk group by the RS-assay (0% to 100%)
86
Change in absolute risk of relapseb in the RS-assay
model (−10% to +10%)
<
Change in utility of
recurrencec (−10% to +10%)




Upper limit cost of
recurrencec
Change in utility following adjuvant
chemotherapy (−10% to +10%)
>
CMF= 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC = 4 cycles of a
a Values in the table show how the incremental impact of the RS-assay compared t
key parameters. For example, if between 42-85% of women identified as intermedia
an ICER between $20,000 / QALY gained and $100,000 / QALY gained; if this propo
$100,000 / QALY gained.
b Relapse includes loco-regional recurrence, distant recurrence and death due to an
c Recurrence includes loco-regional and distant recurrences.group received adjuvant chemotherapy. When the abso-
lute risk of relapse in the RS-assay model increased by ap-
proximately 2% in either pre- or post-menopausal
women, the RS-assay would be dominated by CCP or
associated with negative incremental cost and effect.
We also performed a probabilistic sensitivity analysis
(Figure 2) comparing the RS-assay versus CCP. Wenalysesa














% to 100% 42% to 85% 32% to 41% 0% to 31%
−3% −3% to +0.9% +1% to +2% > +2%
< +9% ≥ +9%
−10% to +10%
−10% to +10%
4.5% −0.8% to +4.5% −2.4% to −0.9% ≤ −2.5%
driamycin, cyclophosphamide; CCP = current clinical practice.
o CCP changes, over 6 significant ranges, depending on the values of certain
te risk by the RS-assay were to receive chemotherapy, then the RS-assay has




Incremental Cost Effectiveness Scatterplot of RS-
assay versus CCP




Incremental Cost Effectiveness Scatterplot of RS-
assay versus CCP






























































































Figure 2 Incremental cost-effectiveness scatterplot and acceptability curve of RS-assay-guided therapy versus CCP-guided therapy for
pre- and post-menopausal women. Sampling distributions and summary estimates of cost, efficacy, and variance were based on 1000
replicates.
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ities and costs) using appropriate distributions (Table 2).
In pre-menopausal women, using a willingneess to pay
threshold of $100,000 per QALY gained, we found that
the RS-assay was the prefered strategy in 54% of simula-
tions (Figure 2a and b). In post-menopausal women, we
found that the RS-assay was the prefered strategy in 62%
of simulations (Figure 2c and d).Discussion
We developed a decision-analytic model to evaluate the
cost effectiveness of the RS-assay versus CCP in ER+/
PR+LN- ESBC. In the base case we estimated that the
RS-assay generated cost savings in pre-menopausal
women and has an ICER of $60,000 per QALY gained in
post-menopausal women.In Canada, an ICER threshold of $100,000 per QALY
gained has been suggested as representing “weak evi-
dence for adoption and appropriate utilization” [27,57],
although there is no evidence that any Canadian
decision-making body has formally implemented this
threshold [58]. The ICERs of the RS-assay in post-
menopausal women were within ranges of a number of
cancer treatments that have recently been approved in
Canada. For instance, sorafinib has an estimated ICER of
$75,821 per life year gained for the treatment of hepato-
cellular carcinoma and has been approved for funding in
Ontario through the Exceptional Access Program [59].
Sunitinib has been funded in all Canadian provinces for
first-line treatment of metastatic renal-cell carcinoma
with an ICER of $144,000 per QALY gained [60].
Previous cost-effectiveness analyses of the RS-assay in
ER+/ PR+LN- ESBC population have several limitations
Hannouf et al. BMC Cancer 2012, 12:447 Page 13 of 15
http://www.biomedcentral.com/1471-2407/12/447and may not be applicable in the Canadian context. One
study [18] did not incorporate results from NSABP B20 [9],
which established the relationship between the RS-assay
and the benefit from using chemotherapy. Another two
studies [19,20] included results from NSABP B20 [19];
however, the treatment strategies that they compared (tam-
oxifen alone for everyone and tamoxifen and chemotherapy
for everyone) do not reflect observed clinical practice in
Canada (Table 3). Other studies from Israel [22] and Japan
[21] did not incorporate all early stage breast cancer com-
plications such as local or regional recurrence. Two recent
studies [23,24] were conducted from the Canadian health
care payer’s perspective; however, the first analysis [23] did
not address all the limitations mentioned above, and mod-
eling the current experience of ER+/ PR+LN- ESBC
population with regard to survival in both analyses
[23,24] was not based on Canadian data and real world
clinical practice. In all studies there was no differenti-
ation in adjuvant chemotherapy practice between pre-
and post-menopausal women as recommended by Can-
adian guidelines [4], whereas we observed differences in
clinical practice for these two groups (Table 3).
Adjuvant chemotherapy is a widely recommended
treatment in ER+/ PR+LN- ESBC [15]. Thus, some have
suggested that large cost savings can be expected by
avoiding chemotherapy treatment in 25% to 35% of
patients based on the results of the RS-assay [15]. Our
analysis suggests that cost savings may be possible in
pre-menopausal women, due the wide use of chemother-
apy in this group, but would likely not occur with post-
menopausal women with ER+/ PR+LN- ESBC.
In sensitivity analysis we addressed the economic im-
pact of uncertainty in clinical guidelines for intermedi-
ate-range RS-assay values (18–30) [61]. Our analysis
demonstrated that the ability of the RS-assay to guide
treatment decisions in the intermediate risk group
likely will be important in determining whether the
RS-assay will be a cost-effective use of resources. If
fewer than 43% of pre-menopausal and 31% of post-
menopausal women identified as intermediate risk by
the RS-assay received adjuvant chemotherapy, then
the RS-assay had negative health effects compared to
CCP. An ongoing prospective clinical trial will further
assess the predictive value of the assay in women in
the intermediate risk group and will be helpful in
verifying our results [10]. However, findings from this
trial will not be available for 5 to 10 years whereas
an adoption decision will need to be made prior to
having the results of this trial.
Our analysis has several limitations. First, there are limits
to what can be ascertained through administrative data. Al-
though the Manitoba Cancer Registry is a highly accurate
source of information about breast cancer [28], errors in
coding can result in incorrect or unrecorded procedures.However, wherever possible we cross validated across data-
bases. For instance, information on breast cancer treat-
ments including surgery, radiation therapy, endocrine
therapy and chemotherapy can be found in both the Mani-
toba Cancer Registry and the administrative databases held
by Manitoba Health and Healthy Living. Second, validation
data for the 21-gene assay was based on retrospective ana-
lyses of the NSABP chemotherapy-tamoxifen trials (B-14
and B-20) conducted in the United States [9,11]. Thus, sur-
vival outcomes by the RS-assay may not reflect the experi-
ence of the ER+/PR+LN- ESBC identified in Manitoba
due to possible differences in patient and tumour character-
istics and treatments. Results from future prospective ana-
lyses of the assay in real-world clinical practice and in
Canadian settings can be used to update our model and
verify our results. Third, there is still uncertainty as to
whether chemotherapy is necessary for women who fall in
the intermediate risk group by the RS-assay [10]. Fourth,
newer third generation anthracycline-taxane regimens have
different costs and slightly better efficacy so analysis with
such data would be more applicable to the current practice
landscape. In addition, our analysis did not account for
growing data on long term side effects of primary adjuvant
chemotherapy such as cardiomyopathy, neuropathy,
leukemia [56]. Finally, although several studies have found
that clinical practice patterns and therapies employed in
the selected time periods in Manitoba reflect practice in
other jurisdictions in Canada [62-64], differences in clinical
practice for women with ER+/PR+LN- ESBC and its asso-
ciated costs across Canadian provinces may still exist.
Conclusions
We compared the RS-assay versus current clinical prac-
tice in ER+/ PR+LN- ESBC for both pre- and post-
menopausal women. We found that it is likely to be
cost-saving for pre-menopausal women and to have an
ICER that is within ranges of a number of cancer treat-
ments recently approved for funding in Canada for post-
menopausal women. Validation of the assay in real-
world clinical practice is warranted to verify the retro-
spective analyses of this assay in clinical trials and en-
sure its cost-effectiveness for routine use in this
population.
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